FuturedMe Inc.
Construction of drug development platform of disease-specific degradation by CANDDY

Program name

Deep-Tech Startups Support Program

Research theme

Construction of drug development platform of disease-specific degradation by CANDDY

Business Plan

In the era of precision medicine, genomic medicine needs to solve the problem (pain) that even if the causative molecule (target) of a disease is identified, there is no therapeutic drug for the target. To this end, we will raise the barrier to entry for CANDDY, the next-generation degradative drug discovery technology, and build a disease-specific degradative drug development platform that will establish a differentiated prototype, expand the market, and reduce side effects.

Research Outline

We are developing a disease-selective CANDDY platform that enables targeted protein degradation specifically in cancer cells by exploiting proteasome isoform differences.

1. Disease-Selective CATs:
   Demonstrating safety and potential applicability across hematologic cancers, solid tumors, and autoimmune diseases.
2. CANCER_Showcase Data:
   Generating in vitro degradation results and in vivo safety and efficacy data.

• Download this page（240KB）